Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Comment by Moneymagnet14on Feb 25, 2015 7:08pm
57 Views
Post# 23465786

RE:RE:RE:RE:RE:RE:RE:Still undervalued

RE:RE:RE:RE:RE:RE:RE:Still undervaluedThis was written another board earlier today. If big pharma already planned to spend over $1.5 billion on 2 of Dr. Hossein's chemical therapies... how much will they eventually spend on 6 to possibly 9 cannabinoid therapies? Look for additional therapy launches (from website) in the future for: Inflammation/Pain/ Huntington's, Epilepsy, Diabetes, Obesity, Cancer & Angiogenesis 3 Big Pharmas worth over $450 billion are committing another billion on Dr. Sazzad Hossein's original discovery, after spending over $500 million already: Teva 48 b Novartis 247b Merk 166b Dr. Sazzad Hossein's old company (XENE) traded as high as $19.28 today after a $9 IPO on November 5th. The market cap was over $200 million on its 5th trading day. The market cap almost reached CDN$ 400 million on January 9th: Market Cap USD$ 280,780,000 ($350 million CDN) Year High 23.50 Year Low 9.21 Today $19.28 "Pharmaceutical partners include Teva Genentech and Merck (through its affiliate, Essex Chemie). These collaborations have aggregately generated more than $140 million in non-equity funding to date, with the potential to provide more than $1.0 billion in future milestone payments"
Bullboard Posts